- Home
- JANX vs ATUS Comparison
JANX vs ATUS Comparison
Compare JANX & ATUS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- JANX
- ATUS
- Stock Information
- Founded
- JANX 2017
- ATUS 2015
- Country
- JANX United States
- ATUS United States
- Employees
- JANX N/A
- ATUS N/A
- Industry
- JANX Biotechnology: Pharmaceutical Preparations
- ATUS Cable & Other Pay Television Services
- Sector
- JANX Health Care
- ATUS Telecommunications
- Exchange
- JANX Nasdaq
- ATUS Nasdaq
- Market Cap
- JANX 1.4B
- ATUS 1.2B
- IPO Year
- JANX 2021
- ATUS 2017
- Fundamental
- Price
- JANX $23.15
- ATUS $2.39
- Analyst Decision
- JANX Strong Buy
- ATUS Hold
- Analyst Count
- JANX 11
- ATUS 6
- Target Price
- JANX $76.55
- ATUS $2.88
- AVG Volume (30 Days)
- JANX 714.6K
- ATUS 4.1M
- Earning Date
- JANX 11-05-2025
- ATUS 11-03-2025
- Dividend Yield
- JANX N/A
- ATUS N/A
- EPS Growth
- JANX N/A
- ATUS N/A
- EPS
- JANX N/A
- ATUS N/A
- Revenue
- JANX $439,000.00
- ATUS $8,762,212,000.00
- Revenue This Year
- JANX N/A
- ATUS N/A
- Revenue Next Year
- JANX $130.50
- ATUS N/A
- P/E Ratio
- JANX N/A
- ATUS N/A
- Revenue Growth
- JANX N/A
- ATUS N/A
- 52 Week Low
- JANX $21.73
- ATUS $1.95
- 52 Week High
- JANX $71.71
- ATUS $3.20
- Technical
- Relative Strength Index (RSI)
- JANX 48.91
- ATUS 46.48
- Support Level
- JANX $21.73
- ATUS $2.35
- Resistance Level
- JANX $24.54
- ATUS $2.79
- Average True Range (ATR)
- JANX 1.07
- ATUS 0.13
- MACD
- JANX -0.06
- ATUS -0.01
- Stochastic Oscillator
- JANX 47.38
- ATUS 17.35
About JANX Janux Therapeutics Inc.
Janux Therapeutics Inc is a clinical-stage biopharmaceutical company developing tumor-activated immunotherapies for cancer. Its proprietary technology has enabled the development of two distinct bispecific platforms: Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr). The TRACTr platform produces T cell engagers (TCEs) with a tumor antigen-binding domain and a CD3 T cell binding domain, while the TRACIr platform produces bispecifics with a tumor antigen-binding domain and a costimulatory CD28 binding domain.
About ATUS Altice USA Inc.
Altice Europe acquired privately held US cable company Suddenlink in 2015 and Cablevision in 2016. Suddenlink's networks provide television, internet access, and phone services to roughly 4.5 million US homes and businesses located primarily in smaller markets, with major clusters in Texas, West Virginia, Idaho, Arizona, and Louisiana. Cablevision provides comparable services to about 5.5 million homes and businesses in the New York City metro area. Both regions now operate under the Optimum brand name. Altice Europe spun off Altice USA, which includes both the Suddenlink and Cablevision operations, to shareholders in 2018. Altice USA also owns News 12 Networks, which broadcasts local news in New York.